> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Group Seeks Removal of ‘Conflicted’ Panel Member
- URL: https://www.fdaweb.com/group-seeks-removal-of-conflicted-panel-member/
- Published: 2018-02-05T12:00:00.000Z
- Updated: 2026-09-14T23:19:41.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140679

Consumer-health advocacy group Citizens for Health has urged FDA commissioner **Scott Gottlieb** to remove a Pew Charitable Trusts representative from the agency’s Pharmacy Compounding Advisory Committee (PCAC) due to alleged conflicts of interest in Pew’s lobbying support for pharmaceutical company interests. PCAC was created in 2014 and makes recommendations to FDA on ingredients and categories of medications that can be used in human compounding. It is made up of 12 voting members, and two non-voting members; Pew holds a voting seat.

“Pew has lobbied side by side with Big Pharma and drug company interests and has lobbied side by side with them in a way that promotes the interests and profits of these companies over the public good,” Citizens for Health said. The group said Pew has acted as a co-signatory with several pharmaceutical trade and public health groups in communications to Congressional members disparaging the practice of pharmacy compounding and calling it unsafe.

Pew director of public health and PCAC panel member **Elizabeth Jungman** told ***FDA Webview*** that her group has a long history of working on drug compounding issues. She said Pew does not accept any financial support from the pharmaceutical industry. Jungman also noted that FDA has rigorous processes and guidelines for choosing committee members and preventing conflicts of interest on panels like PCAC.

Interestingly, Jungman [testified 1/30](http://docs.house.gov/meetings/IF/IF14/20180130/106814/HHRG-115-IF14-Bio-JungmanE-20180130.pdf?ref=fdaweb.com) at a House Energy and Commerce subcommittee hearing on drug compounding and warned that weakening the Drug Quality and Security Act (DQSA), which called for tighter controls on compounding, would threaten patient safety. During her testimony, she shared some new findings showing that the DQSA is spurring better compounding oversight in states.